pipradimadol

{{cs1 config|name-list-style=vanc|display-authors=6}}

{{Infobox drug

| drug_name = Pipradimadol

| image = Pipradimadol v2.svg

| width = 200px

| caption =

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_CA =

| licence_EU =

| DailyMedID =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| dependency_liability =

| addiction_liability =

| routes_of_administration =

| class =

| ATC_prefix =

| ATC_suffix =

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| metabolites =

| onset =

| elimination_half-life =

| duration_of_action =

| excretion =

| CAS_number = 68797-29-5

| CAS_supplemental =

| PubChem = 68883

| IUPHAR_ligand =

| DrugBank =

| ChemSpiderID = 62115

| UNII = CBI6614BOL

| KEGG =

| ChEBI =

| ChEMBL = 148635

| NIAID_ChemDB =

| PDB_ligand =

| synonyms = FU 29-245

| IUPAC_name =2-[1-[2-(2-Chlorophenyl)ethyl]-4-hydroxypiperidin-4-yl]-N-cyclohexyl-N,2-dimethylpropanamide

| C=24 | H=37 | Cl=1 | N=2 | O=2

| SMILES =CC(C)(C(=O)N(C)C1CCCCC1)C2(CCN(CC2)CCC3=CC=CC=C3Cl)O

| StdInChI =1S/C24H37ClN2O2/c1-23(2,22(28)26(3)20-10-5-4-6-11-20)24(29)14-17-27(18-15-24)16-13-19-9-7-8-12-21(19)25/h7-9,12,20,29H,4-6,10-11,13-18H2,1-3H3

| StdInChIKey =CNIMNQJXZKALLC-UHFFFAOYSA-N

}}

Pipradimadol (FU 29-245) is an analgesic, antiserotoninergic agent and potentially an antidepressant.{{cite journal | vauthors = Huegi BS, Ebnöther AM, Rissi E, Gadient F, Hauser D, Roemer D, Hill RC, Buescher HH, Petcher TJ, Mizuta K, Tokushige M, Sahoo RN, Mitra GC, Mohanty PC, Schmoldt A, Benthe HF, Haberland G | title = Synthesis and pharmacological studies of 4,4-disubstituted piperidines: a new class of compounds with potent analgesic properties | journal = Journal of Medicinal Chemistry | volume = 26 | issue = 1 | pages = 42–50 | date = January 1983 | pmid = 6600791 | doi = 10.1021/jm00355a010 }}{{cite journal | vauthors = Oswald I, Adam K, Spiegel R | title = Human EEG slow-wave sleep increased by a serotonin antagonist | journal = Electroencephalography and Clinical Neurophysiology | volume = 54 | issue = 5 | pages = 583–6 | date = November 1982 | pmid = 6181982 | doi = 10.1016/0013-4694(82)90044-x }} The pharmacology is said to be mediated through the opiate receptor. The potency is on the same order of magnitude as for morphine.{{cite patent | country = US | number = 4178377| url = https://patents.google.com/patent/US4178377A/ | title = (4-Hydroxy-4-piperidyl)-alkanoic acid amides | inventor = Rissi E, Ebnother A | assignee = Sandoz AG | gdate = 11 December 1979 | postscript = . }}